Mathematical modelling of HCV infection: What can it teach us in the era of direct-acting antiviral agents?

Antiviral Therapy

Volumn 17, Issue 6 PART B, 2012, Pages 1171-1182

  Chatterjee, Anushree ^a,b   Guedj, Jeremie ^a,c,d   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b CENTER FOR NONLINEAR STUDIES   (United States)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; CILUPREVIR; DACLATASVIR; INTERFERON; MERICITABINE; PEGINTERFERON; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; SILIBININ; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA;

ANTIVIRAL SUSCEPTIBILITY; CELL PROLIFERATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; GROWTH RATE; HEPATITIS C; HUMAN; LIVER CELL; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VIROGENESIS; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KINETICS; MODELS, BIOLOGICAL; PROTEASE INHIBITORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84867267890     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2428     Document Type: Review

References (63)

1. Dahari H, Layden-Almer JE, Kallwitz E, et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology 2009; 136:1402-1409.
2. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010; 51:1176-1184.
3. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
4. Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011; 29:993-1003.
5. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55:192-206.
6. Soriano V, Vispo E, Poveda E, et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011; 66:1673-1686.
7. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003; 38:509-517. (Pubitemid 36919873)
8. Perelson AS, Essunger P, Cao YZ, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191. (Pubitemid 27209434)
9. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586. (Pubitemid 26097216)
10. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol 2002; 2:28-36. (Pubitemid 37328773)
11. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107. (Pubitemid 28471138)
12. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924. (Pubitemid 40037156)
13. Snoeck E, Chanu P, Lavielle M, et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 2010; 87:706-713.
14. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. Aliment Pharmacol Ther 2006; 23:1043-1054. (Pubitemid 43779343)
15. Dahari H, Guedj J, Perelson A, Layden T. Hepatitis C viral kinetics in the era of direct acting antiviral agents and interleukin-28B. Curr Hepat Rep 2011; 10:214-227.
16. Guedj H, Guedj J, Negro F, et al. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with peg-IFN-alfa-2a and ribavirin. J Viral Hepat; doi: 10.1111/j.1365-2893.2011. 01569.x
17. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37:1343-1350. (Pubitemid 36667314)
18. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:28-35. (Pubitemid 30497785)
19. Bochud PY, Bibert S, Negro F, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011; 55:980-988.
20. Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6:e17232.
21. Shudo E, Ribeiro RM, Perelson AS. Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol 2009; 5:321-332.
22. Talal AH, Ribeiro RM, Powers KA, et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006; 43:943-953. (Pubitemid 43724619)
23. Dahari H, Affonso de Araujo ES, Haagmans BL, et al. Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol 2010; 53:460-467.
24. Guedj J, Rong L, Dahari H, Perelson AS. A perspective on modelling hepatitis C virus infection. J Viral Hepat 2010; 17:825-833.
25. Dahari H, Shudo E, Cotler SJ, Layden TJ, Perelson AS. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther 2009; 14:459-464.
26. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46:16-21. (Pubitemid 47171916)
27. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358. (Pubitemid 36667315)
28. Adiwijaya BS, Hare B, Caron PR, et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir Ther 2009; 14:591-595.
29. Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011; 53:1801-1808.
30. Adiwijaya BS, Herrmann E, Hare B, et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 2010; 6: e1000745.
31. Adiwijaya BS, Kieffer TL, Henshaw J, et al. A viral dynamic model for treatment regimens with direct acting anitvirals for chronic hepatitis C infection. PLoS Comput Biol 2012; 8:e1002339.
32. Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139:154-162.
33. Guedj J, Neumann AU. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics. J Theor Biol 2010; 267:330-340.
34. Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004; 48:4784-4792. (Pubitemid 39577685)
35. Dahari H, Sainz B, Jr., Perelson AS, Uprichard SL. Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol 2009; 83:6383-6390.
36. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
37. Domingo E. Biological significance of viral quasispecies. Viral Hepatitis Rev 1996; 2:247-261.
38. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol 2009; 83:5760-5764.
39. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2:30ra32.
40. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-639. (Pubitemid 47436107)
41. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290:1972-1974.
42. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110-113. (Pubitemid 29307577)
43. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003; 77:3007-3019. (Pubitemid 36228086)
44. Appel N, Zayas M, Miller S, et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog 2008; 4:e1000035.
45. Hughes M, Griffin S, Harris M. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 2009; 90:1329-1334.
46. Masaki T, Suzuki R, Murakami K, et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 2008; 82:7964-7976.
47. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4:e1000032.
48. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
49. Powers KA, Ribeiro RM, Patel K, et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006; 12:207-216. (Pubitemid 43273778)
50. Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354:1782-1785.
51. Guedj J, Dahari H, Shudo E, Smith P, Perelson AS. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012; 55:1030-1037.
52. Lawitz E, Rodriguez-Torres M, Denning J, et al. Once daily dual nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV-RNA< LOD at day 14: first purine/pyrimidine clinical combination data (the NUCLEAR study). J Hepatol 2011; 54:S543.
53. Furman PA, Wang P, Niu C, et al. PSI-7851: a novel liver-targeting nucleotide prodrug for the treatment of hepatitis C. Hepatology 2008; 48:1161A.
54. Ma H, Jiang W-R, Robledo N, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor β-d-2′-deoxy- 2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5?-triphosphate species. J Biol Chem 2007; 282:29812-29820. (Pubitemid 350035263)
55. Mihm U, Welker M, Teuber G, et al. HCV viral kinetics during ribavirin monotherapy: results of a randomized partially double blind placebo controlled clinical trial. J Hepatol 2011; 54 Suppl 1:S185.
56. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135:1561-1567.
57. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56:1019-1024.
58. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology 2010; 138:1112-1122.
59. Wagoner J, Morishima C, Graf TN, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS ONE 2011; 6:e16464.
60. Wagoner J, Negash A, Kane OJ, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010; 51:1912-1921.
61. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DYW. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappa B signaling, and HCV infection by standardized silymarin. Gastroenterology 2007; 132:1925-1936. (Pubitemid 46677939)
62. Herrmann E, Zeuzem S, Sarrazin C, et al . Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antivir Ther 2006; 11: 371-376. (Pubitemid 43823556)
63. Reesink HW, Fanning GC, Abou Farha K, et al. Rapid HCV-RNA decline with once daily TMC435: A Phase I Study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138:913-921.